Cost-effectiveness of brexpiprazole adjunctive treatment for major depressive disorder
详细信息 查看全文
- 作者：Matthew Sussmana ; Jeffrey Yua ; Siddhesh A. Kamatb ; Ann Hartryc ; Susan Legacyb ; Ruth Duffyb ; Myrlene Sanon Aigbogunb ; myrlene.sanon@otsuka-us.com" class="auth_mail" title="E-mail the corresponding author
- 关键词：Major depressive disorder ; Cost-effectiveness ; Atypical antipsychotics ; Adjunctive therapy ; Brexpiprazole ; Remission
- 刊名：Journal of Affective Disorders
- 出版年：2017
- 出版时间：1 January 2017
- 年：2017
- 卷：207
- 期：Complete
- 页码：54-62
- 全文大小：590 K
文摘
- •
MDD cost-effectiveness analysis of adjunctive brexpiprazole vs. branded comparators.
- •
A typical antipsychotics increase clinical response and remission at 6 weeks.
- •
Medical care cost savings were observed with the use of brexpiprazole.
- •
Results may help in selecting branded adjunctive treatment for MDD.